Home038290 • KOSDAQ
add
Macrogen Inc
Nakaraang pagsara
₩16,150.00
Sakop ng araw
₩16,210.00 - ₩16,650.00
Sakop ng taon
₩14,920.00 - ₩26,700.00
Market cap
177.01B KRW
Average na Volume
62.86K
P/E ratio
-
Dividend yield
1.82%
Primary exchange
KOSDAQ
Mga balita tungkol sa merkado
MarketWatch
1 araw ang nakalipas
Wall Street sees ‘no alternative’ to U.S. stocks in 2025. Here’s why.
0.072%
Mga Financial
Income Statement
Kita
Net na kita
| (KRW) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 33.00B | 2.20% |
Gastos sa pagpapatakbo | 13.80B | 4.68% |
Net na kita | -3.18B | -60.92% |
Net profit margin | -9.64 | -57.52% |
Kita sa bawat share | — | — |
EBITDA | 2.21B | 47.21% |
Aktuwal na % ng binabayarang buwis | 1.20% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (KRW) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 24.60B | 8.61% |
Kabuuang asset | 274.19B | 3.79% |
Kabuuang sagutin | 124.82B | 40.99% |
Kabuuang equity | 149.37B | — |
Natitirang share | 9.97M | — |
Presyo para makapag-book | 1.09 | — |
Return on assets | -0.54% | — |
Return on capital | -0.70% | — |
Cash Flow
Net change in cash
| (KRW) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -3.18B | -60.92% |
Cash mula sa mga operasyon | -2.08B | 50.99% |
Cash mula sa pag-invest | -9.57B | -22.48% |
Cash mula sa financing | 6.73B | 594.06% |
Net change in cash | -4.51B | 58.99% |
Malayang cash flow | -10.07B | 35.34% |
Tungkol
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
Itinatag
Hun 5, 1997
Website
Mga Empleyado
519
